The clinical diagnostic industry is rapidly transitioning to recombinant proteins, overcoming initial skepticism due to supply chain vulnerabilities and ethical concerns. This shift ensures more reliable and sustainable sourcing for critical diagnostic materials like hormones and cardiac markers. As native protein supplies dwindle, recombinants are becoming the preferred option for their consistent performance and availability.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
0
Ali NematiWritten by Ali
